Drug development for new therapies begins with research and discovery. To treat PWS (Prader-Willi syndrome) and SYS (Schaaf-Yang syndrome), we need to understand the differences between individuals with these conditions and typical individuals, right...
FPWR is pleased to announce that we have recently awarded 13 project awards totaling $1.963M to support research aimed at advancing our understanding of Prader-Willi syndrome (PWS) and developing much-needed treatments. PWS is a complex genetic disor...
Topics: Research
Mice have long been the preferred mammal model in research labs due to their cost, size, and tractable genetics. Their behavioral simplicity, however, limits a researcher’s options for studying the component features that may serve as surrogate measu...
In this one hour and 22-minute video, Dr. Christian Schaaf, Department Chair of Human Genetics at Heidelberg University, discusses current research into Schaaf-Yang syndrome (SYS). Click below to watch the video. If you're short on time, scroll down ...
You are probably aware that individuals with PWS have a slightly elevated risk for thrombosis (blood clot formation), with 8.4% of respondents aged 30-61 years reporting a history of one or more in our 2018-2022 survey, compared to <1% in the non-...
Topics: Research
Do you ever wonder why you’re so strongly motivated to exercise while it seems that some others inexplicably aren’t? The answer may lie in the differences between your gut microbiomes! Nature, the world’s leading multidisciplinary science journal, re...
Topics: Research
As a rare disorder, PWS is most well-known to the medical community and general population for hyperphagia, or intense food-seeking behavior. However, family members, caregivers, and individuals with PWS know that behavior difficulties and mental hea...
Topics: Research
FPWR is investigating several devices that have been proven effective in treating a myriad of symptoms associated with other medical conditions & have considerable potential to relieve symptoms of PWS. Devices offer many advantages including an e...
Topics: Research
You’re probably seen at least one headline heralding the remarkable successes of Novo Nordisk’s drug Wegovy (Semaglutide, 2.4 mg) and Eli Lily’s tirzepatide (currently only approved for type 2 diabetes – likely to be approved for weight loss later th...
Topics: Research
